Cathy Fong Fong Lam

Array ( [id] => 11101129 [patent_doc_number] => 20160298099 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-13 [patent_title] => 'PERMANENT GENE CORRECTION BY MEANS OF NUCLEOTIDE-MODIFIED MESSENGER RNA' [patent_app_type] => utility [patent_app_number] => 15/094926 [patent_app_country] => US [patent_app_date] => 2016-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 11101 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15094926 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12506649 [patent_doc_number] => 09999658 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-06-19 [patent_title] => Method for treating pain and method for screening pharmaceutical compositions having an anti-pain effect [patent_app_type] => utility [patent_app_number] => 15/073660 [patent_app_country] => US [patent_app_date] => 2016-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 11 [patent_no_of_words] => 9260 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15073660 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14637021 [patent_doc_number] => 10363237 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-07-30 [patent_title] => Compositions and methods of inhibiting N-acylethanolamine-hydrolyzing acid amidase [patent_app_type] => utility [patent_app_number] => 15/072194 [patent_app_country] => US [patent_app_date] => 2016-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 16 [patent_no_of_words] => 7747 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 165 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15072194 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12192773 [patent_doc_number] => 09896493 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-02-20 [patent_title] => 'Nucleotide sequence and pharmaceutical composition based thereon with prolonged VEGF transgene expression' [patent_app_type] => utility [patent_app_number] => 15/070239 [patent_app_country] => US [patent_app_date] => 2016-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 9 [patent_no_of_words] => 10194 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 191 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15070239 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10987461 [patent_doc_number] => 20160184406 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-30 [patent_title] => 'COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION' [patent_app_type] => utility [patent_app_number] => 15/065741 [patent_app_country] => US [patent_app_date] => 2016-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 52122 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15065741 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11914293 [patent_doc_number] => 09782462 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-10-10 [patent_title] => 'Modified polynucleotides for the production of proteins associated with human disease' [patent_app_type] => utility [patent_app_number] => 15/060707 [patent_app_country] => US [patent_app_date] => 2016-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 15 [patent_no_of_words] => 213753 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15060707 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12177491 [patent_doc_number] => 20180036427 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-08 [patent_title] => 'METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HIV INFECTION' [patent_app_type] => utility [patent_app_number] => 15/555121 [patent_app_country] => US [patent_app_date] => 2016-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 4353 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15555121 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11120697 [patent_doc_number] => 20160317671 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-03 [patent_title] => 'CELL PENETRATING CONJUGATES AND METHODS OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 15/056777 [patent_app_country] => US [patent_app_date] => 2016-02-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 61 [patent_figures_cnt] => 61 [patent_no_of_words] => 32944 [patent_no_of_claims] => 49 [patent_no_of_ind_claims] => 29 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15056777 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10820546 [patent_doc_number] => 20160166710 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-16 [patent_title] => 'METHOD FOR INCREASING EXPRESSION OF RNA-ENCODED PROTEINS' [patent_app_type] => utility [patent_app_number] => 15/048031 [patent_app_country] => US [patent_app_date] => 2016-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 43132 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15048031 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11449271 [patent_doc_number] => 09572897 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-02-21 [patent_title] => 'Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins' [patent_app_type] => utility [patent_app_number] => 15/042173 [patent_app_country] => US [patent_app_date] => 2016-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 15 [patent_no_of_words] => 183393 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15042173 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11040497 [patent_doc_number] => 20160237454 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-08-18 [patent_title] => 'NON-SILENCING SELECTABLE MARKER GENES AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 15/019838 [patent_app_country] => US [patent_app_date] => 2016-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 29688 [patent_no_of_claims] => 52 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15019838 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16606192 [patent_doc_number] => 10907187 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-02 [patent_title] => Fungal strains and methods of use [patent_app_type] => utility [patent_app_number] => 15/549376 [patent_app_country] => US [patent_app_date] => 2016-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 22004 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15549376 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12150194 [patent_doc_number] => 20180021458 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-25 [patent_title] => 'Optimized RPE65 Promoter and Coding Sequences' [patent_app_type] => utility [patent_app_number] => 15/549549 [patent_app_country] => US [patent_app_date] => 2016-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 15372 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15549549 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11657560 [patent_doc_number] => 09670552 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-06-06 [patent_title] => 'Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene' [patent_app_type] => utility [patent_app_number] => 15/016424 [patent_app_country] => US [patent_app_date] => 2016-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 17 [patent_no_of_words] => 13612 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15016424 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11657559 [patent_doc_number] => 09670551 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-06-06 [patent_title] => 'Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene' [patent_app_type] => utility [patent_app_number] => 15/016366 [patent_app_country] => US [patent_app_date] => 2016-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 17 [patent_no_of_words] => 13716 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15016366 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11480477 [patent_doc_number] => 09587003 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-03-07 [patent_title] => 'Modified polynucleotides for the production of oncology-related proteins and peptides' [patent_app_type] => utility [patent_app_number] => 15/015684 [patent_app_country] => US [patent_app_date] => 2016-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 210026 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15015684 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11923874 [patent_doc_number] => 09791446 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-10-17 [patent_title] => 'Signatures and determinants for distinguishing between a bacterial and viral infection and methods of use thereof' [patent_app_type] => utility [patent_app_number] => 15/015309 [patent_app_country] => US [patent_app_date] => 2016-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 87 [patent_figures_cnt] => 19 [patent_no_of_words] => 81912 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15015309 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17235595 [patent_doc_number] => 11179458 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-23 [patent_title] => Immunogenicity of an optimized synthetic consensus DNA vaccine for porcine epidemic diarrhea virus [patent_app_type] => utility [patent_app_number] => 15/545409 [patent_app_country] => US [patent_app_date] => 2016-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 10 [patent_no_of_words] => 14203 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15545409 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16863863 [patent_doc_number] => 11022601 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-01 [patent_title] => Use of Eomesodermin to determine risk of allograft rejection [patent_app_type] => utility [patent_app_number] => 15/545414 [patent_app_country] => US [patent_app_date] => 2016-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 23 [patent_no_of_words] => 8989 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 155 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15545414 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16815797 [patent_doc_number] => 11000597 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-11 [patent_title] => Engineered receptor/ligand system for delivery of therapeutic agents [patent_app_type] => utility [patent_app_number] => 15/544906 [patent_app_country] => US [patent_app_date] => 2016-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 28776 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15544906 [rel_patent_id] =>[rel_patent_doc_number] =>)